Zobrazeno 1 - 10 of 14 pro vyhledávání: '"David E. Marinier"'
1
Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer
Autor: Yacki Hayashi-Tanner, Peter J. Polewski, Mamatha Gaddam, Nancy R. Fisher, Attila J. Kovacs, David E. Marinier
Publikováno v: Journal of Geriatric Oncology. 13:1011-1016
Increased immune checkpoint inhibitor (ICI) use in various advanced cancer types has led to a parallel rise in immune-related adverse events (irAEs). Despite widespread use, ICI data in older patients remains limited. We investigate irAE prevalence i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78a8c67dc2ea5ce9f474627e7a2182d1
https://doi.org/10.1016/j.jgo.2022.05.007
Zobrazit plný text záznamu
3
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609
Autor: Laurie E, McLouth, Yue, Zheng, Stephanie, Smith, F Stephen, Hodi, Uma N, Rao, Gary I, Cohen, Thomas T, Amatruda, Shaker R, Dakhil, Brendan D, Curti, Ibrahim, Nakhoul, Sreenivasa R, Chandana, Charles L, Bane, David E, Marinier, Sandra J, Lee, Vernon K, Sondak, John M, Kirkwood, Ahmad A, Tarhini, Lynne I, Wagner
Publikováno v: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.
Trial E1609 demonstrated superior overall survival with ipilimumab 3 mg/kg (ipi3) compared to high-dose interferon (HDI) for patients with resected high-risk melanoma. To inform treatment tolerability, we compared health-related quality of life (HRQo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9548358ba2e210d79a7baa98eebb862f
https://pubmed.ncbi.nlm.nih.gov/36029412
Zobrazit plný text záznamu
5
Surgery versus radiation therapy outcomes in patients with clinical stage 0 non-small cell lung cancer
Autor: Matthew McGee, David E. Marinier, Andrew J. Borgert, Susan M. Frankki, Swapna Narayana, Attila J. Kovacs
Publikováno v: Journal of Clinical Oncology. 39:e20537-e20537
e20537 Background: There are currently no clear national guidelines for management of in-situ (stage 0) non-small cell lung cancer (NSCLC). With no prospective clinical trial data, treatment strategies include both surgical resection and definitive r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45524aa0802abaffcc02aa43a29e30eb
https://doi.org/10.1200/jco.2021.39.15_suppl.e20537
Zobrazit plný text záznamu
6
Immune checkpoint inhibitor toxicity and associated outcomes in a geriatric population
Autor: Yacki Hayashi-Tanner, Attila J. Kovacs, David E. Marinier, Mamatha Gaddam, Peter J Polewski, Nancy R Fisher
Publikováno v: Journal of Clinical Oncology. 38:e24014-e24014
e24014 Background: Increased use of immune checkpoint inhibitor (ICI) therapy over various cancer types has resulted in a parallel rise in immune-related adverse events (irAEs). There is limited data with regards to understanding irAEs in the elderly
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::316662cc202fa2e91a07e8116309a647
https://doi.org/10.1200/jco.2020.38.15_suppl.e24014
Zobrazit plný text záznamu
7
Role of adjuvant chemotherapy in patients with pathological stage I NSCLC with high-risk features
Autor: Lubina Arjyal, Andrew J. Borgert, Dipesh Uprety, David E. Marinier, Susan M. Frankki
Publikováno v: Journal of Clinical Oncology. 38:9022-9022
9022 Background: Lobectomy is the current standard of care for patients with stage I non-small cell lung cancer (NSCLC). There is a lack of prospective data on the benefit of adjuvant chemotherapy (CT) in patients with negative margins but with high-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::76e4fb693a3a560e6a378edfe4e6e269
https://doi.org/10.1200/jco.2020.38.15_suppl.9022
Zobrazit plný text záznamu
9
Cytoreductive Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma in the Targeted Therapy Era
Autor: Dipesh Uprety, Amir Bista, Yazhini Vallatharasu, David E. Marinier, Angela L. Smith
Publikováno v: Anticancer research. 38(5)
BACKGROUND/AIM The role of cytoreductive nephrectomy (CN) for metastatic renal cell cancer (mRCC) is not clearly understood after the approval of targeted therapies, particularly in the elderly population. The aim of this study was to compare surviva
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7352ab35289b19e0a9e4b0fba310c8
https://pubmed.ncbi.nlm.nih.gov/29715133
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje